Author: Editor

For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC San Diego with specialties in Leukemia & Lymphoma, Blood & Marrow Transplant, and Medical Oncology, talks about CAR T-cell therapy. For this video update, Dr. Aaron Goodman discusses two main side effects of CAR-T Cell Therapy: Cytokine Release Syndrome and ICANS. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.

For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC San Diego with specialties in Leukemia & Lymphoma, Blood & Marrow Transplant, and Medical Oncology, shares information about CAR T-cell therapy. For this video, Dr. Aaron Goodman gives a brief explanation of three current types of CAR-T cell therapy. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.

For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV Oncology and HIV Stem Cell Transplantation at Miami Cancer Institute, specializing in the treatment of hematologic cancers including leukemia, lymphoma, myelodysplastic syndrome, and myelofibrosis, as well as cancer combined with human immunodeficiency virus (HIV). Dr. Ruiz has unique expertise in bone marrow transplantation, geriatric oncology, and palliative medicine. For this video, Dr. Marco Ruiz discusses the importance of cancer care in HIV-Infected patients, and strategies to improve their care overall. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/.…

For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV Oncology and HIV Stem Cell Transplantation at Miami Cancer Institute, specializing in the treatment of hematologic cancers including leukemia, lymphoma, myelodysplastic syndrome, and myelofibrosis, as well as cancer combined with human immunodeficiency virus (HIV). Dr. Ruiz has unique expertise in bone marrow transplantation, geriatric oncology, and palliative medicine. For this video, Dr. Marco Ruiz discusses how to best handle blood cancers in geriatric patients, and specific issues pertaining to their age group. Thank you to our sponsors! For more, please…

For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV Oncology and HIV Stem Cell Transplantation at Miami Cancer Institute, specializing in the treatment of hematologic cancers including leukemia, lymphoma, myelodysplastic syndrome, and myelofibrosis, as well as cancer combined with human immunodeficiency virus (HIV). Dr. Ruiz has unique expertise in bone marrow transplantation, geriatric oncology, and palliative medicine. For this video, Dr. Marco Ruiz discusses the growing gaps in cancer treatment of ethnic minorities, and how to address those gaps. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/.…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown explains what a biomarker is, and why they are important in cancer. A huge thank you…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown discusses PD-L1 scores in treatment of bladder cancer. A huge thank you to our sponsor! #pfizer…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown examines tumor mutation burden, and explains the role of neoantigens. A huge thank you to our…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown looks at types of immune cells, including lymphocytes and macrophages. A huge thank you to our…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown discusses emerging research on the effect of microbiomes and genomics on immunotherapy in bladder cancer. A…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown explains circulating tumor DNA, and its role in determining immunotherapy effectiveness. A huge thank you to…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Jason Brown looks at how artificial intelligence can be utilized in combining multiple biomarkers. A huge thank you…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Shilpa Gupta discusses the current treatment paradigm for patients with bladder cancer. A huge thank you to our…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Shilpa Gupta discusses the definition of platinum ineligibility and its criteria. A huge thank you to our sponsor!…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine, and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Shilpa Gupta looks at the Keynote 361 study, which examined Pembrolizumab versus Carbo-Gem. A huge thank you to…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine, and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Shilpa Gupta gives a brief overview of the history of first-line therapy in patients unable to take Cisplatin.…

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Petros Grivas, Oncologist with the Seattle Cancer Care Alliance, UW Medicine, and Fred Hutchinson Cancer Research Center, and Dr. Jason Brown, Medical Oncologist at University Hospitals Cleveland Medical Center. In this video, Dr. Petros Grivas discusses the Ambassador Trial, which studied Pembrolizumab in muscle-invasive and locally advanced disease. A huge thank…

Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video series on making high-quality decisions when it comes to cancer care. For this series, Dr. Kwon discusses the decision-making process with Fred, who has been diagnosed with prostate cancer. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this first video, Dr. Kwon and Fred discuss making high-quality decisions and looking at treatment options. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #exelixis #lilly #genentech

Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video series on making high-quality decisions when it comes to cancer care. For this series, Dr. Kwon discusses the decision-making process with Fred, who has been diagnosed with prostate cancer. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss prostate cancer and knowing his options. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #exelixis #lilly #genentech

Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video series on making high-quality decisions when it comes to cancer care. For this series, Dr. Kwon discusses the decision-making process with Fred, who has been diagnosed with prostate cancer. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss when to start treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #exelixis #lilly #genentech

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

EHA 2022 Conference Coverage EHA 2022 (European Hematology Association) Conference Coverage – Synopsis Below EHA 2022 (European Hematology Association) Phase 3, Placebo-Controlled, Randomized Clinical Trial Of PI3K Delta Inhibitor Leniolisib In Patients With Activated PI3K Delta Syndrome. Click Here to watch Just the PI3K Delta Inhibitor Phase 3 Trial Video from EHA 2022 Is Hematopoietic Stem Cell the only APDS Option? V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic). He provides direct clinical care to patients at the NIH Clinical Center. Presented at EHA 2022 the ADPS or Activated PI3K Delta Syndrome is a…

This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts. Claim credit: https://www.achlcme.org/prostate-cancer-onctube

This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts. Claim credit: https://www.achlcme.org/prostate-cancer-onctube

This educational activity features a panel consisting of an oncologist as well as leading experts (a urologist and a researcher) in prostate cancer care considerations in gay and bisexual men (GBM). This panel discusses quality of life considerations and disparities among GBM with prostate cancer. The panel’s aim is to provide clinicians with real-world strategies to facilitate optimal communication and shared decision-making with these patients. This initiative also provides the latest epidemiological and clinical data, controversies, and evolving treatment practices to improve patient-reported outcomes. Additionally, a gay patient shares his prostate cancer story and perspectives to better illustrate and help…

A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy. Claim credit: https://www.achlcme.org/aml-maintenance-therapy-onctube

A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy.Claim credit: https://www.achlcme.org/aml-maintenance-therapy-onctube

A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy. Claim credit: https://www.achlcme.org/aml-maintenance-therapy-onctube

A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy. Claim credit: https://www.achlcme.org/aml-maintenance-therapy-onctube

A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy.Claim credit: https://www.achlcme.org/aml-maintenance-therapy-onctube

This quick, comprehensive video reviews the diagnosis and treatment of cancer- and chemotherapy-induced anemia (CIA). Expert faculty, Dr. Jeffrey Gilreath from University of Utah Hospitals and Clinics discusses the role of intravenous (IV) iron replacement monotherapy, including ferric carboxymaltose (FCM), recent clinical trial data supporting its benefit in treatment of CIA, and management of adverse events in patients receiving this therapy. Claim credit: https://www.achlcme.org/iron-replacement-therapy-onctube

In this dynamic case challenge format, expert faculty work through two patient cases and offer supporting data and practical experience to establish optimal recognition, diagnostic, and treatment practices, and discuss opportunities for shared decision making with patients. Learners are questioned about how they would proceed at different clinical decision points, and faculty commentaries offer recommendations and evidence for next steps. This activity outlines ways to identify and diagnose patients with nonspecific symptoms, differentiate between risk levels, and choose appropriate therapeutic options. Claim credit: https://www.achlcme.org/mds-advances-onctube

In this dynamic case challenge format, expert faculty work through two patient cases and offer supporting data and practical experience to establish optimal recognition, diagnostic, and treatment practices, and discuss opportunities for shared decision-making with patients. Learners are questioned about how they would proceed at different clinical decision points, and faculty commentaries offer recommendations and evidence for next steps. This activity outlines ways to identify and diagnose patients with nonspecific symptoms, differentiate between risk levels, and choose appropriate therapeutic options.   Claim credit: https://www.achlcme.org/mds-advances-onctube

Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC. This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC. Claim…

Myelofibrosis Danazol vs Momelotinib a JAK inhibitor H2 title H3 title 1st Thing You Will Learn In This Article 3rd Thing You Will Learn In This Article 4th Thing You Will Learn In This   It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented to at this year’s EHA. So, the MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib is a JAK inhibitor that differentiates itself from other JAK inhibitors that are already approved for the treatment of myelofibrosis. By a key off target effect on…

Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with immunotherapy. Complementing these stories are insights from experts on the underlying issues fueling disparate access to immunotherapies as well as strategies to overcome treatment barriers for patients in under-resourced communities. Visit https://www.cancercaredisparities.org/ to learn more or claim CME. Help close persistent immunotherapy access gaps to ensure your patients receive the best possible care. Supported by an educational grant from Bristol-Myers Squibb. Special thanks to: Carolyn Jones Productions, Thomas Jefferson University Hospital, and Einstein Medical Center Montgomery.

Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data. Tumor-infiltrating lymphocytes, and tumor-infiltrating lymphocytes recognize tumor antigens. We looked at predictive biomarkers in patients who have received adoptive cell therapy. So just in brief adoptive cell therapy is a fairly complex treatment modality. That’s been administered to patients with melanoma and other tumor types. The idea is that we resect a tumor. That harvest that harbors, both tumor cells and tumor-infiltrating lymphocytes, and that those tumor-infiltrating lymphocytes will actually recognize tumor antigens, but be somewhat exhausted. And that’s why the patient has had tumor growth. If we can expand those…

We completed a geospatial epidemiological study, examining colorectal cancer mortality among those diagnosed before the age of 50. And this is also known as young onset colorectal cancer. So rates of young onset, colorectal cancer, incidents and mortality have been rising rapidly since the mid-nineties with largely unknown patterns and cause. We used data from the underlying cause of death database from CDC wonder for the years, 1999 to 2019 to identify geographic hot and cold spots of young onset colorectal cancer mortality in us counties. So, the overarching result that we found was that geographic patterns of mortality among…

This study led us to the discovery of 53 gene signatures called IMPRINT and with the data we used to develop the signature. We could prove that they could identify patients’ HER2 positive and HER2 negative that could benefit from PD-1 inhibitors. We run a sub-analysis of an I-SPY dataset I-SPY2 is a phase 2 adaptive clinical trial. And we did validate our findings on our independent test set. And when we validate the accuracy of our signature in predicting patient that respond to immunotherapy. We could see that the senior tool had a very high, positive, predictive values about…

APDS or activated PI3KK delta syndrome is a relatively new disease that was only fully characterized in 2013. It is a primary immune dysregulatory disorder which means it is a rare genetic disorder that involves both immune deficiency which shows up as frequent infections and immune dysregulation which can involve things like autoimmunity lymphoproliferation symptoms can vary widely from person to person and in general it’s a progressive disease and can lead to end organ damage as well as malignancies including lymphomas in multiple family members before we get to challenge of treating a disease rare orphan disease like this…

In this interview, I will present the results of a translational analysis of the Italian drug study. AtezoTRIBE is a phase two comparative randomized study, which metastatic colorectal cancer patients were randomized to receive a first line for FOLFOXIRI plus bevacizumab with or without atezolizumab the study method, the primary endpoint showing that the addition of atezolizumab FOLFOXIRI plus Bev prolongs progression-free survival in the overall population, a modest clinical benefit is reported or among patients with proficient is match repair tumors. This results also lead to the search for predictors of benefit from this therapeutic approach. In this perspective…

This study that we presented at ASCO is titled a descriptive study on the treatment and outcomes of patients with platinum sensitive advanced BRCA or PALB2 related pancreatic cancers who have progressed on recappery so basically what this study was is a follow-up study to a phase two clinical trial of patients with platinum sensitive advanced pancreatic cancer who had a germline or somatic pathogenic variant in BRCA1, BRCA2 or PALB2 patients who had who had platinum sensitive disease where were placed on a maintenance recap rib treatment which is a parp inhibitor the clinical question we had was how…

The MM6 trial marks a significant advancement in multiple myeloma treatment, specifically for relapsed or refractory multiple myeloma (RRMM). For example, it evaluates an all-oral regimen combining dexamethasone, ixazomib, and lenalidomide, offering a convenient and effective option for patients. Dexamethasone in Multiple Myeloma: Mechanism and Role Dexamethasone, a potent corticosteroid, is integral to multiple myeloma therapy, addressing queries like “what dexamethasone used for” (8,100 searches) and “dexamethasone is used for” (14,800 searches). For instance, in the MM6 trial, it enhances the efficacy of ixazomib and lenalidomide, making it a cornerstone of the regimen. MM6 Trial Results: Key Findings for Oncologists…

  Article: Transcript: Question – Please Tell Us About The EA 2142 Trial   So, at ASCO 2022 this year I had the opportunity to present the results of the EA 2142 clinical trial this is a randomized phase two study of platinum and a etoposide versus temozolomide and Capecitabine in patients with advanced G3 non-small cell Gastroenteropancreatic    📺 Click to Watch Video 🔊 Click for Audio Only   neuroendocrine neoplasms including both great grade three neuroendocrine tumors and grade 3 neuroendocrine carcinomas so really the reason for this trial being done is that as you’re probably aware high…

  Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it…

  Article: Transcript: Question – Please Tell Us About The 27-gene IO Score Thanks, Stephanie, I appreciate the invitation to interview with you today so I’m going to talk about how the  DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also been previously shown to be associated with response to ICI therapies so this is important because gastric cancer is the fifth most incident    📺Click to Watch Video 🔊Click for Audio Only   cancer worldwide and the third leading cause of cancer-related death worldwide and so unfortunately most…

  CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety…

Audio: So, at ASCO 2022 this year I had the opportunity to present the results of the EA 2142 clinical trial this is a randomized phase two study of platinum and a…Read Full Transcript Here Jennifer R. Eads, MD, Physician Lead GI Clinical Research, Associate Professor of Clinical Medicine, Director of the Neuroendocrine Tumor Program at the University of Pennsylvania. In this interview, she speaks about the ASCO 2022 Abstract – Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. Overview:…

Platinum Chemotherapy: vs. Temozolomide/Capecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD By Jennifer Eads, MD So, at ASCO 2022 this year, I had the opportunity to present the statistically significant results of the EA2142 clinical trial. This is a randomized phase II study of Platinum and Etoposide (platinum chemotherapy) versus Temozolomide and Capecitabine in patients with advanced G-3 non-small cell gastroentero-pancreatic neuroendocrine neoplasms (pancreatic neuroendocrine tumors), including both grade 3 neuroendocrine tumors and grade 3 neuroendocrine carcinomas. The reason for this trial being done is that high-grade neuroendocrine neoplasms are a relatively rare disease entity, and there really…

Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it is…

Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it is…

Audio: Thanks, Stephanie, I appreciate the invitation to interview with you today so I’m going to talk about how the  DetermaIO algorithm and qPCR assay are used to…Read Full Transcript Here Matthew Varga, Ph.D., a multidisciplinary scientist with broad experience in cancer biology, infectious diseases, immunology, molecular biology, and epidemiology, Scientific Affairs at Oncocyte Corporation. In this interview, he speaks about the ASCO 2022 Abstract – The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. Origins: Gastric cancer (GC) is the world’s third greatest cause of cancer-related death.…

DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also been previously shown to be associated with response to ICI therapies so this is important because gastric cancer is the fifth most incident cancer worldwide and the third leading cause of cancer-related death worldwide and so unfortunately most gastric cancers are asymptomatic and go undiagnosed until they are in late stage and so as a result the survival outcomes for late-stage gastric cancers are exceedingly poor and so we need better treatments and detection mechanisms for identifying patients who are…

CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety and…

CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety and…

So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any data. That’s a report on the relative activity of the 2 arms, but let me describe the trial to you because this is a trial for patients, men and with potentially curable hormone receptor, positive breast cancer who are currently being treated or have recently had to stop treatment with an aromatase inhibitor because they really are struggling with the side effects. All of you who treat breast cancer patients will know that we have a significant minority of women…

So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any data. That’s a report on the relative activity of the 2 arms, but let me describe the trial to you because this is a trial for patients, men and with potentially curable hormone receptor, positive breast cancer who are currently being treated or have recently had to stop treatment with an aromatase inhibitor because they really are struggling with the side effects. All of you who treat breast cancer patients will know that we have a significant minority of women…

  Article: Transcript: Question – Please Tell Us About The AMEERA-6 Trial   So, I’m talking about AMEERA-6 which is a trial which is currently ongoing so we don’t yet have any data that reports on the relative activity of the two arms but let me describe the trial to you because this is a trial for patients men and women with potentially curable hormone receptor-positive breast cancer who are currently being treated or have recently had to stop    📺 Click to Watch Video 🔊 Click for Audio Only   treatment with an aromatase inhibitor because they really are…

Audio: Thank you, thanks for the question so this study titled IMP is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer…Read Full Transcript Here Nicholas Coupe, MBBS, Oncologist at Oxford University Hospitals NHS Foundation Trust. In this interview, he speaks about the ASCO 2022 abstract – A phase 1 first-in-human dose-finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL). Origins: Invariant natural killer T-cells (iNKTs) exhibit characteristics of both innate cells (NK-like) and T-cells…

INT230-6 is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer T cell agonist so iNKT cells are sort of a small but important part of the immune system having influence over a number of parts and activated ion key T cells we know have positive effects upon antigen presenting cells which then in turn drives some CD8 T cell responses which are key things in anti-tumorresponses they also promote hearts the effectiveness of natural killer T cells they can also bind directly to tumorcells…

  Article: Transcript: Question – Please Tell Us About the INVINCIBLE Trial.   Thank you, thanks for the question so this study titled IMP is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer T cell agonist so iNKT cells are sort of a small but important part of the immune system having influence over a number of  parts and activated ion key T cells we know    📺 Click to Watch Video 🔊 Click for Audio Only   have positive effects upon antigen presenting…

The GRIFFIN Study is a post-hoc analysis of sustained MRD negative status in the griffin study which treated patients with newly diagnosed multiple myeloma who are transplant eligible with their tumor map Lenalidomide and dexamethasone as the study arm as part of their induction consolidation after transplant and with Daratumumab (DARA) + lenalidomide as maintenance compared to the control arm which was RVd as part of their induction post-transplant consolidation and then maintenance and after all the patients completed two years of maintenance with a median follow-up of 38 years we evaluated sustained MRD negativity lasting 6 months or higher…

Audio: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size and they’re randomized to receive the control which is neoadjuvant Paclitaxel..Read Full Transcript Here Laura Ann Huppert, MD, Hematology/Oncology Fellow, University of California San Francisco. In this interview, she speaks about the ASCO 2022 Abstract – Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial. Synopsis: The goal of this study is to advance personalized medicine by learning which new drug agents are most…

Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura Huppert By Laura Huppert, MD The I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size, and they’re randomized to receive the control, which is neoadjuvant Paclitaxel, followed by AC versus an investigational agent followed by AC. And then the primary endpoint of the study is pathologic complete response rate, or PCR (pathologic complete response). And in this study we basically wanted to look at, there…

Transcript: So the I-SPY2  trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size and they’re randomized to receive the control which is neoadjuvant Paclitaxel followed by ac versus an investigational agent followed by AC and then the primary endpoint of the study is pathologic complete response rate or PCR and the in this study we basically wanted to look at there were a thousand patients that were the 📺 Click to Watch Video 🔊 Click for Audio Only first thousand patients on the…

Audio: The FDA approval of multiple drugs um for the treatment of metastatic unresectable melanoma led to uh the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together..Read Full Transcript Here Brian Gastman, MD is a double boarded Plastic Surgeon and Otolaryngologist with additional fellowships in head and neck surgery, microsurgery and cancer research. Currently, Dr. Gastman is the Medical and Surgical Director of the Melanoma & High-Risk Skin Cancer Program at Cleveland Clinic and leads his translational research laboratory at the Lerner Research Institute. In this interview, he speaks about the ASCO 2022…

T-Vec: + Pembro Advanced Melanoma MASTERKEY-115 Trial Dr Gastman By Brian Gastman, MD The FDA’s approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together. Amgen started a trial initially a different trial with their lead, intratumoral oncolytic virus T-VEC (talimogene laherparepvec), which is based on a virus that was molecularly converted to really have no viral infectious abilities, but could still replicate into tumor cells. The data for its use in patients who had never had immunotherapy with immunotherapy, specifically…

Transcript: The FDA approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together amgen started a trial initially a different trial with their lead intra-tumoral oncolytic virus t-vec which is based on a virus that was molecularly converted to really have no viral infectious abilities but could still replicate into tumor cells the the data for its use in patients who had never had immunotherapy with immunotherapy specifically anti-pd1 from pembrolizumab was an ongoing face retrial after a run-in phase one…

Audio: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak to you today about my talk at ASCO called Taking on Goliath Targeting K-RAS and lung cancer so the meaning behind Goliath here is..Read Full Transcript Here Jia Luo, MD, Thoracic Medical Oncologist, and Cancer Researcher at Harvard University. In this interview, she speaks about the ASCO 2022 Discussion – Taking on Goliath: Targeting Kras in Non–Small Cell Lung Cancer. 📺Click to Watch Video

KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD By Jai Luo, MD Hi there, my name is Jai Luo. I’m a thoracic medical oncologist at Dana Farber. It’s very nice to speak with you today about my talk at ASCO called, “Taking on Goliath: Targeting KRAS in Lung Cancer.” The meaning behind “Goliath” here is that it is a deeply difficult question, but we’ve made a ton of headway, and I think we need to take advantage of the momentum we’ve made in the field to keep advancing it forward. So, my overall takeaway from this…

Transcript: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak to you today about my talk at ASCO called Taking on Goliath Targeting K-RAS and lung cancer so the meaning behind Goliath here is that it is a deeply difficult question but we’ve made a ton of headway and i think we need to take advantage of the momentum we’ve made in the field to keep advancing it forward so my overall take home from this talk is that K-RAS lung cancer is common and an important question we have…

Audio: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the..Read Full Transcript Here Jonathan E. Rosenberg, MD, Chief, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College at Memorial Sloan Kettering Cancer. In this interview, he speaks about the ASCO 2022 Abstract – Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial…

Video: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the..Read Full Transcript Here Jonathan E. Rosenberg, MD, Chief, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College at Memorial Sloan Kettering Cancer. In this video, he speaks about the ASCO 2022 Abstract – Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial…

Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the 24-month two-year follow-up for patients with advanced disease and I think the state is very important because it shows us that there are a proportion of patients who have durable responses the the survival rate at five years for metastatic bladder cancer has historically been around five percent and this and we’ve certainly seen some improvements although still not where it needs to be the…

Transcript – KEYNOTE-716 New Facts You Need To Know – Article Question – Please Tell Us About The KEYNOTE-716 Study. At ASCO 2022 I presented the first analysis of the distant metastasis free survival in the keynote 716 study so this is a study of patients with resected stage 2b and 2c melanoma this is a patient group who actually have a very high risk of recurrence by 24 months many patients have recurred and their prognosis at five years is very poor with a poor overall survival so seven uh 976 patients were randomized one to one with resected…

Transcript – Where is the Elaine 2 Study and Just-in-time Model Right Now? – Article Question – Please Tell Us About The ELAINE II Study. So this was an open label phase two multi-center study looking at Lasofoxifene (LAS) in combination with Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic er positive HER2 negative breast cancer with an ESR1 mutation and this was after progression on prior therapies so as a background ESR1 mutations are a common mechanism of resistance to aromatase inhibitor (AI) therapy and have been associated with poor prognosis in metastatic hormone receptor positive…

Audio: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract –  Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and…

Video: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract –  Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this audio, he speaks about the ASCO 2022 Abstract – Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature. 

DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was an analysis of 926 patients who had undergone breast conserving surgery, with or without radiation therapy and with or without endocrine therapy. They were diagnosed with ductal carcinoma in situ and this came from four groups of patients that were put together. These patients had the DCISionRT assay run on them, and they were broken up into three groups. One was the low-risk group, which was a DCISionRT score of less than or equal to 2.8. One was the elevated…

Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera: An Analysis of Data from the REVEAL Study. Outline Back story PV is characterized by clonal hematopoiesis, which results in higher peripheral blood counts and an increased risk of thrombotic events (TEs). The standard risk model used to…

At this year’s EHA meeting, we presented an abstract from the REVEAL study. Really focusing in on thrombosis risk in patients with polycythemia vera, with respect to their blood counts outside of the adequate the REVEAL study is a very large prospective observational study of patients with polycythemia vera treated in both. Community practices as well as academic practices. And it is a cross-sectional study where we enrolled 2,500 patients, again, four observations. So, there was no therapeutic intervention there. And they were followed for a minimum of 36 months after enrollment. So, we got a pretty good broad swipe…

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, Haematologist with clinical and research interests in multiple myeloma, in particular myeloma, lymphoma and myeloid disorders at St Vincent’s Health Melbourne  and University of Melbourne Australia. In this audio, she speaks about the EHA 2022 Abstract – Carfilzomib, Dexamethasone, And Daratumumab (Kdd) Vs Carfilzomib And Dexamethasone (Kd) In Relapsed/Refractory Multiple Myeloma (Rrmm): Frailty Subgroup Analysis Of The CANDOR Study. History Frailty scores based on age, comorbidities, and functional status can assist in identifying frail patients (pts) at risk of treatment-related toxicity or poor outcomes. An examination of carfilzomib-treated patients in the clinical trials…

The study that I will be discussing today is the frailty subgroup analysis of the CANDOR study, which is a phase 3 study comparing Daratumumab, Carfilzomib and Dexamethasone. That’s Dara KD with KD that’s Carfilzomib and Dexamethasone in patients with relapse refractory, multiple myeloma. Now in the treatment of multiple myeloma sometimes efficacious treatment can result in poor outcome. If patients are FRA and cannot tolerate treatment now we know from the phase three can or study that the triplet combination of Dara KD is effective and result in a 41% relative risk reduction in progression or death compared to…

Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract MOMENTUM: Phase 3 randomized study of Momelotinib (MMB) versus Danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a jak inhibitor. Outline History MMB, a new oral ACVR1/ALK2 and JAK1/2 inhibitor, demonstrated clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. Targets This pivotal…

Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented at EHA 2022. The MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib, a JAK inhibitor that differentiates itself from other inhibitors that are already approved for the treatment of patients with myelofibrosis. What Effects Did Momelotinib Have on ACVR1? A key off-target effect on a molecule called ACVR1, also known as ALK2, It does have the kind of canonical JAK inhibition of JAK2…

Professor Peter Hillmen, MD, he leads the Experimental Haematology section in LICAP and the Translational Haematology Research group. He is a Professor of Experimental Haematology and Honorary Consultant Haematologist at Leeds Teaching Hospitals NHS Trust at University of Leeds. In this audio, he speaks about the EHA 2022 Abstract – The Combination Of Ibrutinib Plus Venetoclax Results In A High Rate Of Mrd Negativity In Previously Untreated Cll: The Results Of The Planned Interim Analysis Of The Phase III Ncri FLAIR Trial. History Ibrutinib (I) and venetoclax (V) both enhance CLL outcomes. I rarely eliminates measurable residual disease (MRD), whereas…

So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3 trial in previous stances, CLL patients which the total trial we recruit just under 1500 patient. What we presented here was the first interim analysis of comparison of Ibrutinib (I) and venetoclax (V) compared to Ibrutinib (I) monotherapy where half the patients had reached 2 years. That was 2,274 patients randomized. So, we analyze over five total that comparison and setting MRD. First of all, we showed that the treatment well tolerated, there were no. Significant tissues with adding the…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this audio, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Backstory: Early-onset pancreatic cancer (EOPC) is uncommon. It is unknown if the incidence of EOPC is increasing or how these patients are being treated. Methodology: We used SEER 2004-2016 to conduct a retrospective population-based investigation. We looked at the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 patients, as well as treatment patterns in 7307 patients (excluding neuroendocrine tumors) under…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this video, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Observation – Origins: Early-onset pancreatic cancer (EOPC) is a rare occurrence. It is unknown whether the prevalence of EOPC is increasing or how these patients are being treated. Methodologies: We used SEER 2004-2016 to conduct a retrospective, population-based analysis. We looked examined the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 individuals, as well as treatment patterns in 7307 patients…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this audio, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Brief Overview: Patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) against placebo in this two-part experiment. In a double-blind design, Part 1 participants will be randomly randomized to either pembrolizumab or…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this video, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Synopsis: In this two-part trial, patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) versus placebo. Part 1 participants will be randomly assigned to either pembrolizumab or placebo in a double-blind design…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this audio, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data. Brief Overview: The FLEX Registry will be a large-scale population-based prospective registry. All patients with stage I to III breast cancer who have MammaPrint® and BluePrint testing on a primary breast tumor are eligible to participate in the FLEX Registry, which is designed to allow for additional study arms…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this video, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.   Synopsis: The FLEX Registry will be set up as a large-scale, population-based prospective registry. All patients with stage I to III breast cancer who obtain MammaPrint® and BluePrint testing on a primary breast tumor are eligible to join the FLEX Registry, which is designed to allow for additional…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this audio, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this video, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Charles Ricordel, MD, PhD, Thoracic Oncologist at CHU de Rennes. In this audio, he speaks about the ASCO 2022 Abstract Abstract 9039: Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with NSQ NSCLC expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Summary: The study duration for an individual patient will begin with the signing of the informed consent and will include a screening period of up to 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days after the last administration of study drug, and at least one follow-up visit after the end-of-treatment…

CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel By Professor Charles Ricordel As many of you may know, antibody drug conjugates are generating a lot of hype right now in the oncology field, and RFT-Sign is a novel antibody drug conjugate that selectively targets CEACAM5. CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5) is a membrane protein that is usually expressed in several epithelial tumor types and might be highly expressed in approximately 25% of non-squamous non-small cell lung cancers. This compound comprises a humanized monoclonal antibody drug conjugates linked to…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this Audio, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this video, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this audio, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.  Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this video, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen. Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Trevor M. Feinstein, MD, Oncologist, Hematologist at Piedmont Cancer Institute. In this audio, he speaks about the ASCO 2022 Abstract – DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires. Synopsis: Lung cancer is the biggest cause of cancer-related death globally. In 2018, there were a projected 2.09 million new cases and 1.76 million deaths worldwide, according to the World Health Organization’s Global Cancer Observatory (GLOBOCAN, 2018, Fact Sheet N039). China has a relatively high incidence and…

Plinabulin Improved OS and lower Toxicity in NSCLC EGFR Wild Type The DUBLIN-3 was a randomized phase III trial from BeyondSprings Pharmaceuticals in non-small cell lung cancer. It looked at an advanced non-small cell lung cancer, EGFR wild type. And I was looking at second and third-line treatment. Patients had to progress through at least one line of therapy, but two lines of progression were okay. And patients had to have been exposed to platinum-based therapy. The randomized clinical trial was pretty broad in that it took patients with an ECOG performance status of 2 or better, and they had…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this audio, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this video, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this audio, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this video, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Audio: So I’m Dr. Gabriel Chiosis. I’m a professor and member at Sloan-Kettering Cancer Center and I’m going to discuss today our work or an overview first of our approach to treatment which is to target 1330 interaction networks rather than a protein or an interact or the interaction of two proteins as generally or at least historically we think about therapy, and the paper I was invited to discuss is it’s a protocol we published recently our cells…Read Full Transcript Here Gabriela Chiosis, Ph.D., Researcher at Memorial Sloan Kettering Cancer Center. In this video, she speaks a Gabriela Chiosis,…

Protocol Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks I’m going to discuss today our work or an overview first of our approach to treatment, which is to target 1313 interaction, rather than a protein or an Interact or interaction of 2 proteins as generally or at least historically we think about therapy. And the paper I was invited to discuss is it’s a protocol we published recently. In cancer cells SAR protocols, and it’s called Synthesis of Labeled Epichaperome Probes and assessment in visualizing pathologic protein interaction networks in tumor-bearing mice. Understanding Epichaperome Probes…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Steven Ansell, MD, PhD, Professor of Medicine at Mayo Clinic. In this video, he speaks about the ASCO Abstract – First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Origins: To date, an overall survival (OS) benefit from innovative therapy combinations over conventional treatments in first-line classical Hodgkin lymphoma has seldom been demonstrated (cHL). The development of more active medicines for relapsed/refractory illness has made demonstrating increased OS with first-line therapy difficult. In ECHELON-1 (NCT01712490), 5-year follow-up studies supported the long-term progression-free survival (PFS) benefit of first-line…

The clinical trial that we are discussing is Echelon-1. This is a study specifically for patients with advanced-stage Hodgkin’s lymphoma stages 3 and 4, and it’s a study really evaluating the addition of new novel targets to frontline therapy. Brentuximab vedotin is an antibody-drug conjugate that has been very successful in patients with Hodgkin’s lymphoma in the relapse setting. And now is being tested in the frontline in comparison to ABVD chemotherapy. So, the echelon one trial compared brentuximab vedotin and ABVD chemotherapy. To a standard of care which is ABVD chemotherapy. And the key findings have been reported over…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Clinical Data Management Tools Enables Flexibility and ScalabilitySupporting Evolving Oncology Clinical Study Designs   OncologyTube was privileged to feature Mike Keens, Executive Vice President, Anju Software (https://www.anjusoftware.com), and Stefan Michiels, Head of Department of Biostatistics and Epidemiology, Gustave Roussy (https://www.gustaveroussy.fr/en).  These gentlemen discussed key aspects of oncology clinical trial enrollment challenges and solutions, especially during and post COVID-19 pandemic.   At the outset of COVID-19 during the first quarter of 2020, enrollment within most clinical trials stopped – apart from COVID-19 vaccine trials.  Between March 2020 and May 2020, all ongoing trials scrambled to continue visits at home or attempted…

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL. A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL.   A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…

EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR Cell And Gene Therapy Programs  EXUMA Biotech, Corp., is a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors.  EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22. CAR-TaNKs are potent cancer killers with T and NK features, which preclinically have been observed to reproducibly and robustly expand in vivo in lymphoreplete animal models following the generation of synthetic lymph nodes post subcutaneous injection. Based…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:    The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:   The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview:   The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview: The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target for…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines.   Overview:   To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs).   Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines. Overview: To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs). Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and castration-resistant PC, as…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting strategy…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View   Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.